Related Experiment Video
Updated: Oct 8, 2025
Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
A Glimpse in the Future of Malignant Mesothelioma Treatment
Gaetano Pezzicoli1, Mimma Rizzo2, Martina Perrone1
1Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, Bari, Italy.
Abstract:
Malignant mesothelioma (MMe) is a rare neoplasm with few therapeutic options available. The landscape of effective therapy for this disease remained unchanged in the last two decades. Recently, however, the introduction of Immune Checkpoint Inhibitors (ICIs) led to small, but nevertheless, promising improvements. However, many efforts are still needed to radically improve the prognosis of MMe. In this review, we analyze all those therapeutic strategies for MMe that are still in a preclinical or early clinical phase of development. In particular, we focus on novel antiangiogenic drugs and their possible combination with immunotherapy. Furthermore, we describe also more complex strategies such as microRNA-loaded vectors, oncolytic viruses, and engineered lymphocytes.
Insights
Malignant mesothelioma treatments are limited, but new immunotherapies show promise. This review explores emerging preclinical and early-stage therapies, including novel antiangiogenic drugs and complex strategies, to improve patient outcomes.
Area of Science:
- Oncology
- Immunotherapy
- Drug Development
Background:
- Malignant mesothelioma (MMe) is a rare cancer with historically limited therapeutic options.
- The treatment landscape for MMe has seen minimal change over the past two decades.
- Recent advancements include the introduction of Immune Checkpoint Inhibitors (ICIs), offering modest but encouraging improvements.
Purpose of the Study:
- To review novel therapeutic strategies for malignant mesothelioma in preclinical and early clinical development.
- To focus on the potential of combining novel antiangiogenic drugs with immunotherapy.
- To explore advanced therapeutic approaches like microRNA-loaded vectors, oncolytic viruses, and engineered lymphocytes.
Main Methods:
- Literature review of preclinical and early-phase clinical studies.
- Analysis of emerging therapeutic strategies for malignant mesothelioma.
- Focus on targeted therapies, immunotherapies, and combination approaches.
Main Results:
- Emerging therapies show potential for improving malignant mesothelioma prognosis.
- Novel antiangiogenic drugs combined with immunotherapy represent a promising avenue.
- Complex strategies including gene therapy and cell-based therapies are under investigation.
Conclusions:
- Significant unmet needs remain in malignant mesothelioma treatment.
- Further research and development of novel therapies are crucial for improving patient outcomes.
- Investigating innovative approaches like antiangiogenic drugs, immunotherapy combinations, and advanced strategies is essential.
